Human medicines European public assessment report (EPAR): Melatonin Neurim, melatonin, Sleep Initiation and Maintenance Disorders, Date of authorisation: 07/11/2022, Revision: 1, Status: Authorised
Melatonin Neurim is a medicine used on its own for the short-term treatment of primary insomnia (poor quality of sleep) in patients aged 55 years or over. ‘Primary’ means that the insomnia does not have any identified cause, including any medical, mental or environmental cause.
Melatonin Neurim contains the active substance melatonin.
This medicine is the same as Circadin, which is already authorised in the EU. The company that makes Circadin has agreed that its scientific data can be used for Melatonin Neurim (‘informed consent’).
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
